Eligibility & Testing

Talk to your doctor about using the Oncotype DX Genomic Prostate Score (GPS) test and whether it's right for you. If your doctor orders the test, no additional procedures are needed—samples from your most recent biopsy will be analyzed to provide information on the aggressiveness of your tumor.

Is the test right for you?

You could be eligible for the Oncotype DX GPS test if you have:

icon Biopsy within 3 years

icon Not started treatment

icon Localized prostate cancer*

* Excludes NCCN® very-high risk prostate cancer

Three simple steps to get the test

With your Genomic Prostate Score result, you and your doctor will have even more information you need to help create a plan that is right for you.



The Oncotype DX GPS test is conducted on a small tissue sample already taken from your most recent biopsy.


About 2 weeks after your biopsy arrives at the Exact Sciences laboratory, your GPS result will be available to your doctor. Your results will include your level of risk for prostate cancer death and metastasis within 10 years after surgery, as well as your risk for adverse pathology.2-5


You and your doctor can use your results to help understand your options and discuss what's next for you.

The Oncotype DX GPS test is covered by Medicare (for eligible patients with NCCN® Very Low-, Low-, Intermediate-, and High-risk prostate cancer). Private insurance coverage varies.


  1. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. V.2.2021.
  2. Van Den Eeden et al. Eur Urol. 2017.
  3. Klein et al. Eur Urol. 2014.
  4. Cullen et al. Eur Urol. 2015.
  5. Cullen et al. Urology. 2020.
*Adverse pathology will not be reported for Gleason 4+3 patients due to the aggressive nature of their disease.

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer V.2.2021. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed June 1, 2021. To view the most recent and complete version of the guideline, go online to NCCN.org.

Making cancer care smarter.®